The Roles of Pyroptosis in Tumor Immune Microenvironment and Tumor Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 1933
Special Issue Editors
Interests: experimental pharmacology and cancer immunotherapy
Special Issue Information
Dear Colleagues,
Pyroptosis was long regarded as caspase-1-mediated monocyte death in response to certain bacterial insults. Caspase-1 is activated upon various infectious and immunological challenges through different inflammasomes. The discovery of caspase-11/4/5 function in sensing intracellular lipopolysaccharide expands the spectrum of pyroptosis mediators and also reveals that pyroptosis is not cell-type specific. Recent studies have identified the pyroptosis executioner, gasdermin D (GSDMD), a substrate of both caspase-1 and caspase-11/4/5. GSDMD represents a large gasdermin family bearing a novel membrane pore-forming activity. Thus, pyroptosis has been redefined as gasdermin-mediated programmed necrosis. Tumor immune microenvironment (TIME) includes tumor cells, immune cells, cytokines, etc. The interactions between these components, which are divided into anti-tumor and pro-tumor, determine the trend of anti-tumor immunity. Although the immune system can eliminate tumors through the cancer-immune cycle, tumors appear to eventually evade immune surveillance by shaping an immunosuppressive microenvironment. Immunotherapy reshapes the TIME and restores the tumor-killing ability of anti-tumor immune cells. Pyroptosis represents the newly discovered immunogenic cell death (ICD) forms. Promoting ICD may alter the tumor microenvironment (TME) and the influx of tumor-infiltrating lymphocytes (TILs). Combining their inducers and immune checkpoint inhibitors (ICIs) is synergistic in enhancing antitumor effects.
The goal of this Special Issue is to provide a forum to advance research on the contribution of pyroptosis of tumor cells to the reconstruction of tumor immune microenvironment, which further influences the progression of various diseases. Additionally, these novel findings could be used to develop approaches for the diagnosis, treatment, and prognosis of cancer.
Original research articles, methods, reviews, and mini reviews are welcome. Specific areas of interest for thise Special Issue include, but are not limited to, the following:
- Mechanisms of pyroptosis in cancer cells;
- Association between pyroptosis of tumor cells and immune cell infiltration;
- Combination therapy of tumor cells pyroptosis inducers and tumor immunity;
- Pathways of pyroptosis and prognostic model of cancers;
- Impact of pyroptosis of tumor cells on cancer immunotherapy;
- Cancer biotherapy (gene therapy, cell therapy, mRNA, peptides, etc.) targeting pyroptosis pathway;
- Nanomedicine for cancers based on pyroptosis pathways.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope for this section and will not be accepted as part of this Special Issue.
Dr. Chen Li
Dr. Lei Huang
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pyroptosis
- tumor immune microenvironment
- tumor immunotherapy
- inflammation
- programmed cell death
